

Nathan A Pennell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3093418/publications.pdf>

Version: 2024-02-01

156
papers

16,748
citations

81743

39
h-index

17055

122
g-index

163
all docs

163
docs citations

163
times ranked

28410
citing authors

#	ARTICLE	IF	CITATIONS
1	The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. <i>Clinical Lung Cancer</i> , 2022, 23, 108-115.	1.1	8
2	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
3	Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 407-413.	1.9	4
4	Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. <i>Journal of Thoracic Oncology</i> , 2022, 17, 179-181.	0.5	5
5	Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. , 2022, 10, e003778.		26
6	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. <i>The Lancet Healthy Longevity</i> , 2022, 3, e143-e152.	2.0	16
7	The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. <i>JCO Oncology Practice</i> , 2022, 18, 578-583.	1.4	23
8	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
9	Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al. , 2022, 10, e005086.		0
10	Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS ^{G12C} Mutation. <i>New England Journal of Medicine</i> , 2022, 387, 120-131.	13.9	269
11	A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8595-TPS8595.	0.8	7
12	Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3353-3356.	0.8	2
13	Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 4410-4424.	3.2	6
14	Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 822-829.	1.9	37
15	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021, 26, 523-532.	1.9	4
16	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	0.8	54
17	MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. <i>JCO Precision Oncology</i> , 2021, 5, 653-663.	1.5	50
18	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 7490.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. <i>European Journal of Cancer</i> , 2021, 148, 146-158.	1.3	18
20	Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor–Mutant Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 679.	3.4	0
21	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 3071-3078.	1.3	11
22	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
23	The CoVID–TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID–19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
24	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 18174.	1.6	15
25	Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Blood</i> , 2021, 138, 3223-3223.	0.6	0
26	Impact of EGFR mutation and ALK rearrangement on the outcomes of non–small cell lung cancer patients with brain metastasis. <i>Neuro-Oncology</i> , 2020, 22, 267-277.	0.6	22
27	Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. <i>Blood Advances</i> , 2020, 4, 5966-5975.	2.5	124
28	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
29	Impact of the COVID-19 Pandemic on Healthcare Workers’ Risk of Infection and Outcomes in a Large, Integrated Health System. <i>Journal of General Internal Medicine</i> , 2020, 35, 3293-3301.	1.3	33
30	Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	13.9	505
31	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). <i>Annals of Oncology</i> , 2020, 31, S1202-S1203.	0.6	11
32	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
33	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , 2020, 395, 1907-1918.	6.3	1,395
34	Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. <i>Oncologist</i> , 2020, 25, 921-924.	1.9	9
35	Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. <i>Oncologist</i> , 2020, 25, 562-e1012.	1.9	26
36	Nab–paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum–based doublet chemotherapy. <i>Cancer</i> , 2020, 126, 1060-1067.	2.0	13

#	ARTICLE	IF	CITATIONS
37	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	13.7	1,966
38	Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening. <i>Oncologist</i> , 2020, 25, 364-365.	1.9	1
39	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2020, 136, 56-58.	0.6	3
40	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101
41	A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States. <i>Journal of Clinical Oncology</i> , 2020, 38, 9529-9529.	0.8	10
42	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	2.3	284
43	Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?. <i>Journal of Thoracic Disease</i> , 2020, 12, 5042-5045.	0.6	1
44	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
45	Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
46	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. <i>Journal of Clinical Oncology</i> , 2019, 37, 2360-2367.	0.8	52
47	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. <i>Nature Communications</i> , 2019, 10, 5143.	5.8	15
48	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of $\geq 1\%$ by the USA Food and Drug Administration. <i>Annals of Oncology</i> , 2019, 30, 1686-1688.	0.6	20
49	Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 531-542.	1.8	210
50	The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 369-372.	0.6	9
51	Time to initial cancer treatment in the United States and association with survival over time: An observational study. <i>PLoS ONE</i> , 2019, 14, e0213209.	1.1	179
52	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100126.	0.7	24
53	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	0.8	159
54	Patterns of Recurrence and Overall Survival in Incidental Lung Cancer in Explanted Lungs. <i>Annals of Thoracic Surgery</i> , 2019, 107, 891-896.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Nonâ€“Small-Cell Lung Cancer Using a Decision Analytic Model. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	81
56	An Openâ€“Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Nonâ€“Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 457.	1.9	0
57	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. <i>Oncologist</i> , 2019, 24, 4-8.	1.9	7
58	Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study. <i>Blood</i> , 2019, 134, 3651-3651.	0.6	3
59	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Nonâ€“Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e335-e348.	1.1	53
60	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 14-21.	0.9	21
61	â€œMy Patient Was Diagnosed With Nontargetable Advanced Nonâ€“Small Cell Lung Cancer. What Now?â€• Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 696-707.	1.8	5
62	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018, 10, 3909-3921.	0.6	35
63	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	6
64	High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. <i>Lung Cancer</i> , 2018, 126, 48-54.	0.9	4
65	Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. <i>PLoS ONE</i> , 2018, 13, e0197743.	1.1	50
66	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	7.7	422
67	Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1771-1775.	0.5	157
68	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1393-1399.	0.5	169
69	Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9031-9031.	0.8	33
70	PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage nonâ€“small-cell lung cancer (ES-NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12059-12059.	0.8	0
71	Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18710-e18710.	0.8	0
72	Identifying delays in care for patients with NSCLC using value-stream mapping.. <i>Journal of Clinical Oncology</i> , 2018, 36, 136-136.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
74	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer. <i>Chest</i> , 2017, 152, 271-281.	0.4	381
75	P2.03a-040 Safety and Efficacy of Nab-Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S912-S913.	0.5	0
76	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
77	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	0.9	40
78	Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. <i>Seminars in Hematology</i> , 2017, 54, 198-204.	1.8	29
79	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 144-154.	1.8	17
80	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57
81	Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab. <i>Journal of Clinical Oncology</i> , 2017, 35, 11547-11547.	0.8	5
82	Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 6557-6557.	0.8	9
83	Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts). <i>Journal of Clinical Oncology</i> , 2017, 35, 8504-8504.	0.8	18
84	Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. <i>Journal of Clinical Oncology</i> , 2017, 35, e20647-e20647.	0.8	3
85	A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2598-TPS2598.	0.8	3
86	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 144-154.	1.8	9
87	Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. <i>Annals of Translational Medicine</i> , 2017, 5, 378-378.	0.7	6
88	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 51-58.	0.4	2
89	Precision oncology experience at a tertiary care center. <i>Journal of Clinical Oncology</i> , 2017, 35, e18118-e18118.	0.8	0
90	Phase II study of stereotactic radiosurgery or other local ablation followed by erlotinib for patients with EGFR mutation who have previously progressed on an EGFR tyrosine kinase inhibitor (TKI). <i>Journal of Clinical Oncology</i> , 2017, 35, e20623-e20623.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Association of delays in time to surgery for resectable stage IIIA non-small cell lung cancer with survival.. Journal of Clinical Oncology, 2017, 35, e20056-e20056.	0.8	0
92	Fast-Growing Plasmacytoma. American Journal of the Medical Sciences, 2016, 351, 308.	0.4	1
93	Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute. Journal of Oncology Practice, 2016, 12, e101-e107.	2.5	7
94	A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 2016, 7, 11428.	5.8	136
95	Best Practices in Treatment Selection for Patients with Advanced NSCLC. Cancer Control, 2016, 23, 2-14.	0.7	7
96	Adjuvant Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer. Chest, 2016, 149, 1357-1359.	0.4	0
97	Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute, 2016, 108, .	3.0	70
98	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 569.	3.4	5
99	Evaluation of radiomic features on baseline CT scan to predict clinical benefit for pemetrexed based chemotherapy in metastatic lung adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 11582-11582.	0.8	3
100	Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.. Journal of Clinical Oncology, 2016, 34, 11603-11603.	0.8	6
101	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. Journal of Clinical Oncology, 2016, 34, 9059-9059.	0.8	2
102	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9079-9079.	0.8	4
103	Patient-centered outcomes with post-approval nivolumab in metastatic NSCLC at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology, 2016, 34, 29-29.	0.8	0
104	Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.. Journal of Clinical Oncology, 2016, 34, e14073-e14073.	0.8	0
105	Preoperative neutrophil lymphocyte ratio as a predictor of outcomes in patients with early stage non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e23069-e23069.	0.8	0
106	The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e21688-e21688.	0.8	0
107	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1547-1552.	3.3	115
108	Biofeedback Assisted Stress Management in Patients with Lung Cancer: A Feasibility Study. Applied Psychophysiology Biofeedback, 2015, 40, 201-208.	1.0	12

#	ARTICLE	IF	CITATIONS
109	Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S3-S10.	0.8	96
110	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 1298-1303.	1.9	19
111	Hereditary implications of somatic tumor testing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1523-1523.	0.8	5
112	Prospective clinical study of precision oncology in solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6585-6585.	0.8	4
113	Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6609-6609.	0.8	2
114	Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6565-6565.	0.8	1
115	Lung cancer treatment outcomes in recipients of lung transplant. <i>Translational Lung Cancer Research</i> , 2015, 4, 784-91.	1.3	9
116	RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1714-1719.	0.5	40
117	High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 646-653.	0.5	28
118	ALK Status Testing in Non-Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material. <i>Journal of Thoracic Oncology</i> , 2014, 9, 464-468.	0.5	57
119	Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. <i>Investigational New Drugs</i> , 2014, 32, 362-368.	1.2	36
120	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 158-163.	0.9	47
121	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , 2014, 511, 543-550.	13.7	4,572
122	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7514-7514.	0.8	35
123	Circulating tumor cells enrichment and characterization in ALK-translocation positive lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19025-e19025.	0.8	0
124	Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12515-e12515.	0.8	0
125	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. <i>Journal of Clinical Oncology</i> , 2014, 32, 191-191.	0.8	5
126	Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. <i>Practical Radiation Oncology</i> , 2013, 3, 301-306.	1.1	33

#	ARTICLE	IF	CITATIONS
127	ALK Status Testing in Non-Small Cell Lung Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 341-346.	1.2	115
128	New Guideline Sets the Ground Rules for Routine Molecular Testing in Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 413-414.	1.2	0
129	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. <i>Translational Lung Cancer Research</i> , 2013, 2, 251-5.	1.3	8
130	ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2013, 2, E1-3.	1.3	0
131	Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib. <i>Journal of Oncology Practice</i> , 2012, 8, 34s-37s.	2.5	1
132	Superior vena cava syndrome in lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 309-315.	1.5	0
133	Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1200-1201.	0.5	3
134	XL647: A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 219-226.	0.5	51
135	Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?. <i>Current Treatment Options in Oncology</i> , 2012, 13, 478-490.	1.3	4
136	Selection of chemotherapy for patients with advanced non-small cell lung cancer. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S46-S50.	0.6	10
137	Treating acquired resistance to EGFR-tyrosine kinase inhibitors: still a work in progress. <i>Translational Lung Cancer Research</i> , 2012, 1, 149-51.	1.3	2
138	Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2011, 12, 350-359.	1.1	15
139	Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer. <i>Clinical Lung Cancer</i> , 2011, 12, 94-99.	1.1	1
140	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4417-4424.	0.8	405
141	Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. <i>Oncologist</i> , 2009, 14, 399-411.	1.9	86
142	Phase I/II Trial of the Addition of Erlotinib to Pre- and Postoperative Chemotherapy/Hyperfractionated Radiotherapy, and as Maintenance, for Resectable Mediastinoscopy-defined Stage III Non-small-cell Lung Cancer (NSCLC): Report on the Phase II Component. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, S58.	0.4	0
143	Investigational agents in the management of non-small cell lung cancer. <i>Current Oncology Reports</i> , 2009, 11, 275-284.	1.8	5
144	Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1156-1162.	0.5	22

#	ARTICLE	IF	CITATIONS
145	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827.	15.2	1,015
146	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 317-323.	2.4	185
147	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. <i>Biomarkers in Medicine</i> , 2007, 1, 203-207.	0.6	2
148	Patients as real time teachers. <i>Journal of Cancer Education</i> , 2007, 22, 131-133.	0.6	0
149	Interns' Work Hours. <i>New England Journal of Medicine</i> , 2005, 352, 726-728.	13.9	18
150	Reactive microgliosis. <i>Progress in Neurobiology</i> , 1999, 57, 563-581.	2.8	1,074
151	Tracing of fluoro-gold prelabeled microglia injected into the adult rat brain. , 1998, 23, 84-88.		12
152	Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1998, 86, 1-12.	1.1	160
153	Colonization of neural allografts by host microglial cells: Relationship to graft neovascularization. <i>Cell Transplantation</i> , 1997, 6, 221-230.	1.2	19
154	Characterization of Myomodulin-Related Peptides From the Pulmonate Snail <i>Helix aspersa</i> . <i>Peptides</i> , 1997, 18, 1099-1106.	1.2	21
155	Colonization of Neural Allografts by Host Microglial Cells: Relationship to Graft Neovascularization. <i>Cell Transplantation</i> , 1997, 6, 221-230.	1.2	31
156	Lectin staining of sheep microglia. <i>Histochemistry</i> , 1994, 102, 483-486.	1.9	21